Krish S Krishnan sold $8.2M of KRYS
President and CEO at Krystal Biotech, Inc.. 50,000 shares at an average of $164.80, traded Dec 13, 2024, filed Dec 13, 2024.
Score components
- +25RoleCEO
- +25Trade size$8.2M at market
- 0Share of holdings soldSold 3.2% of holdings
- +8Cluster2 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001298709-24-000017, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 13, 2024 | SOpen-market sale Common Stock10b5-1 | -6,302 | $163.07 | $1.0M | 1,555,960 | Dec 13, 2024 |
| Dec 13, 2024 | SOpen-market sale Common Stock10b5-1 | -8,381 | $163.91 | $1.4M | 1,547,579 | Dec 13, 2024 |
| Dec 13, 2024 | SOpen-market sale Common Stock10b5-1 | -4,909 | $164.93 | $810k | 1,542,670 | Dec 13, 2024 |
| Dec 13, 2024 | SOpen-market sale Common Stock10b5-1 | -1,977 | $165.82 | $328k | 1,540,693 | Dec 13, 2024 |
| Dec 13, 2024 | SOpen-market sale Common Stock10b5-1 | -923 | $166.93 | $154k | 1,539,770 | Dec 13, 2024 |
| Dec 13, 2024 | SOpen-market sale Common Stock10b5-1 | -911 | $169.65 | $155k | 1,538,859 | Dec 13, 2024 |
| Dec 13, 2024 | SOpen-market sale Common Stock10b5-1 | -957 | $170.47 | $163k | 1,537,902 | Dec 13, 2024 |
| Dec 13, 2024 | SOpen-market sale Common Stock10b5-1 | -640 | $171.63 | $110k | 1,537,262 | Dec 13, 2024 |
| Dec 13, 2024 | SOpen-market sale Common Stockindirect: By Spouse10b5-1 | -5,942 | $163.04 | $969k | 1,494,940 | Dec 13, 2024 |
| Dec 13, 2024 | SOpen-market sale Common Stockindirect: By Spouse10b5-1 | -8,923 | $163.92 | $1.5M | 1,486,017 | Dec 13, 2024 |
| Dec 13, 2024 | SOpen-market sale Common Stockindirect: By Spouse10b5-1 | -4,723 | $164.92 | $779k | 1,481,294 | Dec 13, 2024 |
| Dec 13, 2024 | SOpen-market sale Common Stockindirect: By Spouse10b5-1 | -2,114 | $165.79 | $350k | 1,479,180 | Dec 13, 2024 |
| Dec 13, 2024 | SOpen-market sale Common Stockindirect: By Spouse10b5-1 | -798 | $166.96 | $133k | 1,478,382 | Dec 13, 2024 |
| Dec 13, 2024 | SOpen-market sale Common Stockindirect: By Spouse10b5-1 | -200 | $168.31 | $34k | 1,478,182 | Dec 13, 2024 |
| Dec 13, 2024 | SOpen-market sale Common Stockindirect: By Spouse10b5-1 | -953 | $169.48 | $162k | 1,477,229 | Dec 13, 2024 |
| Dec 13, 2024 | SOpen-market sale Common Stockindirect: By Spouse10b5-1 | -727 | $170.43 | $124k | 1,476,502 | Dec 13, 2024 |
| Dec 13, 2024 | SOpen-market sale Common Stockindirect: By Spouse10b5-1 | -620 | $171.62 | $106k | 1,475,882 | Dec 13, 2024 |
Related signals
Other insiders at Krystal Biotech, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 38Weak | Krystal Biotech, Inc. | Krish S Krishnan President and CEO | $9.0M 25,000 shares | -2% | |
| 33Weak | Krystal Biotech, Inc. | Suma Krishnan President, R&D | $9.0M 25,000 shares | -2% | |
| 45Moderate | Krystal Biotech, Inc. | Krish S Krishnan President and CEO | $8.9M 50,000 shares | -3% | |
| 40Moderate | Krystal Biotech, Inc. | Suma Krishnan President, R&D | $8.9M 50,000 shares | -3% | |
| 6Weak | Krystal Biotech, Inc. | Kathryn Romano Chief Accounting Officer | $131k 750 shares | -6% | |
| 33Weak | Krystal Biotech, Inc. | Suma Krishnan President, R&D | $8.2M 50,000 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.